B Douglas Smith

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction
    B Douglas Smith
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231 1000, USA
    Am J Med 125:S26-30. 2012
  2. ncbi Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Leuk Res 35:87-94. 2011
  3. ncbi K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA
    Clin Cancer Res 16:338-47. 2010
  4. ncbi Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
  5. ncbi Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
  6. ncbi High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
  7. ncbi Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 117:3302-10. 2011
  8. ncbi Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
    Amer M Zeidan
    Division of Hematologic Malignancies, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Br J Haematol 158:198-207. 2012
  9. ncbi 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 17:754-8. 2011
  10. ncbi Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
    Amy Sexauer
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 120:4205-14. 2012

Detail Information

Publications62

  1. ncbi Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction
    B Douglas Smith
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231 1000, USA
    Am J Med 125:S26-30. 2012
    ..Efforts to improve patient awareness of their disease severity and establishing clear treatment goals are crucial for setting up an individualized treatment plan and ensuring optimal patient and caregiver satisfaction...
  2. ncbi Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Leuk Res 35:87-94. 2011
    ..We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF...
  3. ncbi K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA
    Clin Cancer Res 16:338-47. 2010
    ..A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia...
  4. ncbi Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
    ..We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML...
  5. ncbi Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
    ..Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients...
  6. ncbi High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  7. ncbi Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 117:3302-10. 2011
    ..This clinical trial is registered at www.clinicaltrials.gov as #NCT00470197...
  8. ncbi Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
    Amer M Zeidan
    Division of Hematologic Malignancies, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Br J Haematol 158:198-207. 2012
    ..In summary, the CLO-CYx4 regimen was well tolerated and had activity in patients with RRAL, especially relapsed ALL. Therefore, CLO-CYx4 can be considered a salvage therapy for adults with RRALs, and warrants further investigations...
  9. ncbi 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 17:754-8. 2011
    ..5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted...
  10. ncbi Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
    Amy Sexauer
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 120:4205-14. 2012
    ..The present study is the first description of terminal differentiation of cancer cells in patients treated with a tyrosine kinase inhibitor. These data highlight the importance of the differentiation block in the patho-genesis of AML...
  11. ncbi Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes
    Erica D Warlick
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
    Leuk Res 32:1439-47. 2008
    ..These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients...
  12. ncbi Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 119:55-63. 2012
    ..The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials.gov as #NCT00602771...
  13. ncbi Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    ..Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury...
  14. ncbi Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells
    Christopher G Kanakry
    Division of Hematologic Malignancies, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Blood 117:608-17. 2011
    ..Further insight into this oligoclonal regulatory T-cell population will be fundamental toward developing effective immunomodulatory techniques to improve survival for patients with AML...
  15. ncbi Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies
    Ying Ye
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 69:8482-90. 2009
    ....
  16. ncbi FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
    Takashi Sato
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 117:3286-93. 2011
    ..These findings could have important implications regarding the design and outcome of trials of FLT3 inhibitors and furthermore suggest a rationale for targeting FL as a therapeutic strategy...
  17. ncbi Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia
    Elizabeth A Griffiths
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Epigenetics 5:590-600. 2010
    ..Methylation of tumor suppression genes (TSGs) is common in myeloid malignancies. However, application of this as a molecular marker for risk stratification in patients with AML is limited...
  18. ncbi Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  19. ncbi In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
    Mark Levis
    Department of Oncology, Baltimore, MD 21231, USA
    Blood 104:1145-50. 2004
    ..These results should be considered when designing trials combining chemotherapy with each of the FLT3 inhibitors currently in clinical development...
  20. ncbi A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Blood 110:1762-9. 2007
    ..This clinical trial is registered with the National Cancer Institute's PDQ at www.clinicaltrials.gov as no. JHOC-J0561...
  21. ncbi Strategies to eliminate cancer stem cells: clinical implications
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
    Eur J Cancer 42:1293-7. 2006
    ..Re-examining both our pre-clinical and clinical drug development paradigms to include the cancer stem cell concept has the potential to revolutionize the treatment of many cancers...
  22. ncbi Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005
    ..However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL...
  23. ncbi A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia
    Jonathan M Gerber
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Blood 119:3571-7. 2012
    ..ALDH activity appears to distinguish normal from leukemic CD34(+)CD38(-) cells and identifies those AML cells associated with relapse...
  24. ncbi Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ..These findings warrant continuing development of flavopiridol at 50 mg/m2/d x 3 days in combination with cytotoxic and biological agents for acute leukemias...
  25. ncbi Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
    Judith E Karp
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 14:3077-82. 2008
    ..Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR...
  26. ncbi Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Br J Haematol 128:853-62. 2005
    ..The combined use of pharmacologic differentiating agents and growth factors may improve the clinical efficacy of differentiation therapy in APL...
  27. ncbi Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Lymphoma 51:1711-9. 2010
    ....
  28. ncbi Characterization of chronic myeloid leukemia stem cells
    Jonathan M Gerber
    Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Am J Hematol 86:31-7. 2011
    ..These expression patterns suggest that PROTEINASE 3, SURVIVIN, and hTERT are not optimal therapeutic targets in CML stem cells; whereas PRAME and WT1 seem promising...
  29. ncbi Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  30. ncbi High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 11:93-100. 2005
    ..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated...
  31. ncbi Characterization of clonogenic multiple myeloma cells
    William Matsui
    Sidney Kimmel Comprehensive Cancer Center, John Hopkins University School of Medicine, Bunting Blaustein Cancer Research Bldg, Rm 245, 1650 Orleans St, Baltimore, MD 21231, USA
    Blood 103:2332-6. 2004
    ..These data suggest that MM "stem cells" are CD138- B cells with the ability to replicate and subsequently differentiate into malignant CD138+ plasma cells...
  32. ncbi A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
    Mark Levis
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231-1000, USA
    Blood 99:3885-91. 2002
    ..These findings form the basis for a planned clinical trial of CEP-701 in patients with AML harboring FLT3- activating mutations...
  33. ncbi Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, MD, USA
    Leuk Lymphoma 54:483-90. 2013
    ..Seventeen (81%) received intensification (median 30 days to intensification). Brief, anthracycline-sparing, intensive cyclophosphamide (BASIC) therapy yields durable remissions in poorer-risk BL/atypical BL...
  34. ncbi Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution
    Amy E Dezern
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:1404-9. 2011
    ..Our single-institution study of consecutively treated AML patients supports the hypothesis that allogeneic transplant in early CR1 improves the long-term outcomes for FLT3/ITD AML...
  35. ncbi Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Br J Haematol 121:251-8. 2003
    ..These results suggest that the differentiating activities of IFN-alpha may play a role in its clinical antimyeloma activity and provide the rationale for clinical differentiation therapy in MM...
  36. ncbi Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
    Judith E Karp
    Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 113:4841-52. 2009
    ..These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853...
  37. ncbi Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
    Mark Levis
    Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Blood 108:3477-83. 2006
    ..Additionally, our results suggest that nonselectivity may constitute an important component of the cytotoxic effect of FLT3 inhibitors in FLT3-mutant AML...
  38. ncbi The role of growth factors in the activity of pharmacological differentiation agents
    William H Matsui
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cell Growth Differ 13:275-83. 2002
    ..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...
  39. ncbi Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
    Mark Levis
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Blood 117:3294-301. 2011
    ..This study is registered at www.clinicaltrials.gov as #NCT00079482...
  40. ncbi High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  41. ncbi Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients
    Maria Cristina Villarroel
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Bldg, Room 1M52, Baltimore, MD 21231 1000, USA
    Invest New Drugs 30:2096-102. 2012
    ..In conclusion, sorafenib is highly protein bound in human plasma with a higher affinity towards albumin and limited free drug may be partly responsible for its borderline clinical activity...
  42. ncbi What are the endpoints of therapy for acute leukemias? Old definitions and new challenges
    B Douglas Smith
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Lymphoma Myeloma 9:S296-301. 2009
    ....
  43. ncbi Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib
    Brady Stein
    Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Ther 32:804-20. 2010
    ..However, its use is complicated by development of resistance or drug intolerance, prompting dose escalation or a trial of dasatinib or nilotinib, the second-generation tyrosine kinase inhibitors (TKIs)...
  44. ncbi A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 846:1-7. 2007
    ..96. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods (<15%)...
  45. ncbi Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant
    Greg R Angstreich
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 207, Baltimore, MD 21231, USA
    Curr Opin Oncol 16:95-9. 2004
    ..The impacts of both are in part limited because of their toxicity profiles. Ongoing laboratory investigations and clinical trials remain paramount to providing the best treatment approach for our patients with chronic myeloid leukemia...
  46. ncbi Cancer stem cells: are we missing the target?
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Natl Cancer Inst 96:583-5. 2004
  47. ncbi Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
    Haematologica 97:1736-42. 2012
    ..6 months...
  48. ncbi Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
    Clin Cancer Res 18:6723-31. 2012
    ..To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776...
  49. ncbi A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice
    Natini Jinawath
    Institute of Genetic Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Mol Diagn 11:359-63. 2009
    ....
  50. ncbi New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation
    Ting Bao
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 3:287-96, 302. 2005
    ..This review will focus on several exciting components of these pathways and the agents targeting these pathways that are entering clinical trials...
  51. ncbi Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry
    Ming Zhao
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Anal Biochem 337:143-8. 2005
    ..99. The values for both within-day and between-day precision and accuracy were <15%. This method was used to characterize the plasma pharmacokinetics of bryostatin 1 at doses of 20 microg/m2) to optimize treatment with this agent...
  52. ncbi Concise review: Emerging concepts in clinical targeting of cancer stem cells
    Zeshaan A Rasheed
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Stem Cells 29:883-7. 2011
    ..We will review current evidence supporting the role of CSCs in clinical oncology and discuss potential barriers and strategies in designing trials examining CSC-targeting agents...
  53. ncbi The paradox of response and survival in cancer therapeutics
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Blood 107:431-4. 2006
    ..In this article, we discuss the evidence for cancer stem cells in hematologic malignancies and possible ways to begin targeting these cells and measuring clinical effectiveness of such treatment approaches...
  54. ncbi Curing acute myelogenous leukemia: still a major challenge
    B Douglas Smith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Res 29:607-8. 2005
  55. ncbi Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
    Mark Levis
    Blood 106:673-80. 2005
    ..Taken together, these experiments establish that the FLT3/ITD mutations are present in leukemia stem cells, and that FLT3 inhibitors may have activity against these cells...
  56. ncbi Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
    Kathleen M Murphy
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, USA
    J Mol Diagn 5:96-102. 2003
    ..Here we describe the performance characteristics of the assay, assay validation, and our clinical experience using this assay to analyze 147 clinical specimens...
  57. ncbi Trying to improve clinical outcome in AML: lessons from negative trials
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 289, Baltimore, Maryland 21231-1000, USA
    Leuk Res 29:603-4. 2005
  58. ncbi Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    B Douglas Smith
    Departments of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 103:3669-76. 2004
    ..Our results show that FLT3 inhibition is associated with clinical activity in AML patients harboring FLT3-activating mutations and indicate that CEP-701 holds promise as a novel, molecularly targeted therapy for this disease...
  59. ncbi The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo
    Rebecca C Osthus
    Program in Human Genetics and Molecular Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 65:5620-7. 2005
    ..We observed a significant increased incidence of transgenic animal solid tumors, which were not seen in littermate controls. These observations suggest that JPO1/CDCA7 may contribute to Myc-mediated tumorigenesis...
  60. ncbi Ribonucleotide reductase: an old target with new potential
    B Douglas Smith
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21210, USA
    Leuk Res 27:1075-6. 2003
  61. ncbi Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  62. ncbi FLT3 inhibitors in acute myeloid leukemia
    Khaled el-Shami
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Expert Rev Hematol 1:153-60. 2008
    ....